Reviewing eFFECTOR Therapeutics (NASDAQ:EFTR) & Spruce Biosciences (NASDAQ:SPRB)

Spruce Biosciences (NASDAQ:SPRB) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Profitability

This table compares Spruce Biosciences and eFFECTOR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
eFFECTOR Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Spruce Biosciences and eFFECTOR Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	3	4	0	2.38
eFFECTOR Therapeutics	0	0	0	0	0.00

Spruce Biosciences presently has a consensus price target of $170.10, indicating a potential upside of 141.28%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Spruce Biosciences is more favorable than eFFECTOR Therapeutics.

Risk and Volatility

Spruce Biosciences has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Insider and Institutional Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Spruce Biosciences and eFFECTOR Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	19.67	-$38.97 million	($51.72)	-1.36
eFFECTOR Therapeutics	N/A	N/A	-$35.81 million	($13.08)	0.00

eFFECTOR Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Spruce Biosciences beats eFFECTOR Therapeutics on 7 of the 12 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.